Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511388 · ClinicalTrials.gov registry record
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 400
- Enrollment target
NCT06511388: Clinical Trial study, sponsored by Mayo Clinic.
NCT06511388 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06511388 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 400 participants
- Enrollment target
Study Summary
This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
Primary Outcome
Changes in myocardial function will be assessed using 2D-STE derived strain rate. Changes will be compared to baseline over time.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2016-01-20 |
| Est. Completion | 2024-10-09 |
Why NCT06511388 stopped before completion
NCT06511388 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06511388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06511388 about?
NCT06511388 is a clinical study titled "Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study". This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
What is the current status of trial NCT06511388?
This trial is currently terminated. The enrollment target is 400 participants. The study started on 2016-01-20. Estimated completion is 2024-10-09.
What interventions are being tested in trial NCT06511388?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06511388?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI